Reprogramming the Immune System: How Cancer’s CAR T Therapy is Being Pivoted to Fight Autoimmune Disease
Table of Contents
For Jan Janisch-Hanzlik, the progression of multiple sclerosis wasn’t just a medical diagnosis; it was a slow erasure of her autonomy. A former nurse, Janisch-Hanzlik found herself forced into a desk job and living in a home modified for a wheelchair she hoped she would never need. The standard pharmacological interventions had failed to halt her decline, leaving her in a state of precarious instability where frequent falls became a daily risk.
Her turning point came when she entered a clinical trial at the University of Nebraska Medical Center in Omaha. Janisch-Hanzlik wasn’t testing a traditional drug, but rather a radical reprogramming of her own biology through CAR T cell therapy—a treatment originally engineered to kill aggressive blood cancers.
From Oncology to Autoimmunity
The logic behind pivoting CAR T (Chimeric Antigen Receptor T-cell) therapy from cancer to autoimmune conditions lies in the shared role of B cells. In the context of oncology, B cells can proliferate uncontrollably, leading to leukemias and lymphomas. By engineering a patient’s own T cells to express a specific receptor—the CAR—scientists can program these immune cells to hunt and destroy malignant B cells with surgical precision.
In autoimmune diseases, the problem isn’t the quantity of B cells, but their behavior. In patients with multiple sclerosis, lupus, or vasculitis, B cells mistakenly produce antibodies that attack the body’s own healthy tissues. The hypothesis is straightforward: if CAR T can wipe out cancerous B cells, it can also wipe out the “rogue” B cells driving autoimmune destruction. The goal is not just symptom management, but a systemic reset—essentially clearing the slate so the immune system can reboot without the diseased memory.
The Clinical Evidence
The transition from theory to practice began in earnest around 2021, when a German research team reported successful results using the therapy for a patient with lupus. Since then, the scope of investigation has broadened significantly. One of the most striking examples comes from the University of Colorado Anschutz, where neurologist Amanda Piquet has been evaluating the therapy for stiff person syndrome—a rare condition characterized by debilitating muscle rigidity and spasms for which there is currently no FDA-approved treatment.
In a study involving 26 participants, the results were telling. Prior to treatment, many patients struggled with a mechanical gait, and nearly half relied on walkers or canes. By 16 weeks post-treatment, the majority showed increased walking speeds, and eight participants had abandoned their assistive devices for short distances entirely. By the final follow-up, the company behind the trial, Kyverna, reported that all 26 patients had ceased using other immunotherapies.
The Risks of a Biological Reset
Despite the promise, reprogramming the immune system is an invasive and high-stakes procedure. The very mechanism that makes CAR T effective—the aggressive activation of T cells—can trigger a systemic inflammatory response known as cytokine release syndrome (CRS). This can manifest as dangerously high fevers and low blood pressure, and in severe cases, can lead to neurological complications such as confusion and drowsiness.
For patients like Janisch-Hanzlik, the decision to undergo the procedure involves a calculated gamble. The treatment requires a period of intense monitoring and carries the uncertainty of how long the remission will last. However, for those with genetic predispositions to these diseases, the motivation often extends beyond personal recovery. As Janisch-Hanzlik noted, the hope is that pioneering these treatments today will pave the way for future generations to avoid the same struggle.
While the FDA first approved CAR T for leukemia in 2017, the current wave of trials suggests we are entering a new era of precision medicine where the line between cancer treatment and autoimmune therapy is increasingly blurred.
